HER2 발현이 낮은 국소 진행성 또는 전이성 유방암 치료를 위한 RC48-ADC 연구
HER2 발현이 낮은 국소 진행성 또는 전이성 유방암 치료를 위한 RC48-ADC의 효능 및 안전성을 평가하는 무작위, 통제, 다기관 3상 임상 연구
This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Binghe Xu, M.D.
- 전화번호: 010-87788826
- 이메일: bhxu@hotmail.com
연구 장소
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100021
- 모병
- Oncology Hospital, Chinese Academy of Medical Sciences
-
연락하다:
- Binghe Xu
- 전화번호: 010-87788826
- 이메일: bhxu@hotmail.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Voluntarily agree to participate in the study and sign the informed consent;
- Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
- Expected survival ≥12 weeks;
- Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
- For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
- Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
- Bone marrow function:
hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;
- Liver function (according to the normal value of the clinical trial center) :
serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis
- Renal function (according to the normal value of the clinical trial center) :
serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;
- Cardiac function:
American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;
- Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
- The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
- Previous use of anthracycline drugs;
- Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
- Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
- The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
- There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
- Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
- According to the RECIST 1.1 standard, there is at least one measurable lesion.
Exclusion Criteria:
- Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
- The research drug was used within 4 weeks before the start of study administration;
- Have undergone major surgery within 4 weeks before the start of study administration;
- Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
- Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
- Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
- There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
- Suffering from active infection requiring systemic treatment;
- Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
- The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
- Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
- Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
- There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
- Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
- Subjects who are not suitable for using any of the alternative control drugs;
- The presence of brain metastases and / or cancerous meningitis;
- Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
- Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: RC48-ADC
RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis. |
RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
다른 이름들:
|
|
활성 비교기: Physician's Choice
Physician's Choice: HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis. Physician's choice from the following options: Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets |
Administered according to label, as one option for Physician's Choice (determined before randomization)
다른 이름들:
Administered according to label, as one option for Physician's Choice (determined before randomization)
다른 이름들:
Administered according to label, as one option for Physician's Choice (determined before randomization)
다른 이름들:
Administered according to label, as one option for Physician's Choice (determined before randomization)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
기간: within approximately 3 years
|
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard. |
within approximately 3 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS), evaluated by the investigator
기간: within approximately 3 years
|
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard. |
within approximately 3 years
|
|
Objective remission rate (ORR)
기간: within approximately 3 years
|
The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed). |
within approximately 3 years
|
|
Duration of relief (DOR)
기간: within approximately 3 years
|
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death |
within approximately 3 years
|
|
Disease control rate (DCR)
기간: within approximately 3 years
|
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study. |
within approximately 3 years
|
|
Tumor progression time (TTP)
기간: within approximately 3 years
|
Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation). |
within approximately 3 years
|
|
Overall survival (OS)
기간: within approximately 3 years
|
Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject. |
within approximately 3 years
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Yu Jiang, West China Hospital
- 수석 연구원: Binghe Xu, Oncology Hospital, Chinese Academy of Medical Sciences
- 수석 연구원: Wei Li, Jilin University First Hospital
- 수석 연구원: Xiaojia Wang, Zhejiang Cancer Hospital
- 수석 연구원: Ying Wang, Sun Yat-sen University Cancer Prevention and Control Center
- 수석 연구원: Ning Liao, Guangdong Provincial People's Hospital
- 수석 연구원: Haibo Wang, Qingdao University Hospital
- 수석 연구원: Quchang Ouyang, Hunan Cancer Hospital
- 수석 연구원: Yueyin Pan, Anhui Provincial Hospital
- 수석 연구원: Yingying Du, The First Affiliated Hospital of Anhui Medical University
- 수석 연구원: Jin Yang, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
- 수석 연구원: Xiuwen Wang, Qilu Hospital of Shandong University
- 수석 연구원: Huihua Xiong, Tongji Hospital
- 수석 연구원: Xinhong Wu, Hubei Cancer Hospital
- 수석 연구원: Weimin Xie, Cancer Hospital Affiliated to Guangxi Medical University
- 수석 연구원: Xin Zhou, Chongqing University Cancer Hospital
- 수석 연구원: Li Ran, Cancer Hospital of Guizhou Province
- 수석 연구원: Yu Wang, Shanxi Province Cancer Hospital
- 수석 연구원: Jinnan Gao, Bethune Hospital of Shanxi Province
- 수석 연구원: Jingfen Wang, Linyi Cancer Hospital
- 수석 연구원: Xianhe Xie, First Affiliated Hospital of Fujian Medical University
- 수석 연구원: Ru Zeng, The First Affiliated Hospital of Xiamen University
- 수석 연구원: Airong Wang, Weihai Municipal Hospital
- 수석 연구원: Zhengqiu Zhu, The Affiliated Hospital of Xuzhou Medical University
- 수석 연구원: Sanyuan Sun, Xuzhou Central Hospital
- 수석 연구원: Qingshan Li, Affiliated Hospital of Chengde Medical College
- 수석 연구원: Aimin Zang, Affiliated Hospital of Hebei University
- 수석 연구원: Liuzhong Yang, The First Affiliated Hospital of Xinxiang Medical College
- 수석 연구원: Meili Sun, Jinan Central Hospital
- 수석 연구원: Liang Li, Zibo Central Hospital
- 수석 연구원: Guohua Yu, Weifang People's Hospital
- 수석 연구원: Xujuan Wang, Neijiang Second People's Hospital
- 수석 연구원: Ying Wang, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- 수석 연구원: Ying Cheng, Jilin Provincial Tumor Hospital
- 수석 연구원: Jifeng Feng, Jiangsu Cancer Institute & Hospital
- 수석 연구원: Tao Sun, Liaoning Cancer Hospital & Institute
- 수석 연구원: Yuee Teng, First Hospital of China Medical University
- 수석 연구원: Shu Wang, Peking University People's Hospital
- 수석 연구원: Min Yan, Henan Cancer Hospital
- 수석 연구원: Changlu Hu, Anhui Provincial Cancer Hospital
- 수석 연구원: Zhongsheng Tong, Tianjin Cancer Hospital Airport Hospital
- 수석 연구원: Lihua Song, Shandong Cancer Hospital and Institute
- 수석 연구원: Yunjiang Liu, Hebei Medical University Fourth Hospital
- 수석 연구원: Jing Cheng, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- 수석 연구원: Peng Shen, First Affiliated Hospital of Zhejiang University
- 수석 연구원: Liangming Zhang, Yantai Yuhuangding Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 피부병
- 유방 질환
- 피부 및 결합 조직 질환
- 유방 신생물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 알칼로이드
- 인돌
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 뉴 클레오 시드
- 우라실
- 피리 미디 논
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 데 옥시 리보 뉴 클레오 시드
- Fluorouracil
- 도세탁셀
- 카페시타빈
- 비노렐빈
- 파클리탁셀
기타 연구 ID 번호
기타 연구 ID 번호
- RC48-C012
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .